Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad IPO

This article was originally published in The Gray Sheet

Executive Summary

Proteomics collaboration with Hitachi and Oracle to identify drug targets is prepping to go public, according to the firm. Collaborators on the project, which is currently dubbed Myriad Proteomics, are waiting for amenable market conditions to launch an initial public offering. The operation, including a fully functioning data-generating facility in Salt Lake City with a 65-member staff, was launched in 2001 to compete with Celera Genomics (1"The Gray Sheet" April 23, 2001, In Brief). Myriad contributed $82 mil. in technology to the alliance, retaining a 50% stake in the $185 mil. venture...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT016697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel